Synthesis and anticonvulsant properties of new 1-(2-pyridinyl)- 3-substituted pyrrolidine-2,5-dione derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 65, Issue 4, 2008, Pages 457-465

  Kamińskp, Krzysztof ^a   Obniska, Jolanta ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Anticonvulsant activity; l (2 pyridinyl) succinimides; Pyrrolidine 2,5 diones

Indexed keywords

CYCLOHEXANE; METHYL GROUP; PENTETRAZOLE; PYRIDINE; SUCCINIMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; ROTAROD TEST; SEIZURE;

ANIMALS; ANTICONVULSANTS; MALE; MICE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINIMIDES;

EID: 49949115897     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kenda B.M., Matagne A.C., Talaga P.E., et al.: J. Med. Chem. 47, 530 (2004).
2. Dimmock J.R., Vashishtha S.C., Stables J.P.: Eur. J. Med. Chem. 35, 241 (2000).
3. Bruno-Blanch L., Gálvez J., Garcia-Domenech R.: Bioorg. Med. Chem. Lett. 13, 2749 (2003).
4. Estrada E., Perm A.: Bioorg. Med. Chem. 8, 2755 (2000).
5. Brodie M. J.: Epilepsy Res. 45, 3 (2001).
6. Deshmukh T.R., Kadaba P.K.: Med. Chem. Res. 3, 223 (1993).
7. Pavia M.R., Lobbestael S.J., Taylor C.P., Hershenson F.M., Miskell D.L.: J. Med. Chem. 33, 854 (1990).
8. Ho B., Crider A.M., Stables J.P.: Eur. J. Med. Chem. 36, 265 (2001).
9. White D.C., Greenwood T.D., Downey A.L., Bloomquist J.R., Wolfe J.F.: Bioorg. Med. Chem. 12, 5711 (2004).
10. Obniska J., Zejc A., Karolak-Wojciechowska J.: Farmaco 54, 423 (1999).
11. Zejc A., Obniska J., Chojnacka-Wójcik E., Tatarczyńska E., Wiczyńska B.: Pol. J. Pharmacol. Pharm. 39, 91 (1987).
12. Zejc A., Obniska J., Wilimowski M., Rutkowska M., et al.: Pol. J. Pharmacol. Pharm. 42, 69 (1990).
13. Obniska J., Kulig K., Zejc A.: Acta Pol. Pharm. Drug Res. 55, 223 (1998).
14. Obniska J., Zejc A., Zagórska A.: Acta Pol. Pharm. Drug Res. 59, 209 (2002).
15. Obniska J., Zagórska A.: Farmaco 58, 1227 (2003).
16. Kamiński K., Obniska J., Zagórska A., Mating D.: Arch. Pharm. Chem. Life Sci. 339, 255 (2006).
17. Scott K.R., Moore J.A., Zalusky T.B., Nicholson J.M., Lee M.: J. Med. Chem. 28, 413 (1985).
18. Moal H. : Bull. Soc. Chim. France 1, 418 (1956).
19. Miller C.A., Long L.M.: J. Am. Chem. Soc. 73, 4895 (1951).
20. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., Swinyard E.A.: Epilepsia 19, 409 (1978).
21. Kupferberg H.J.: Epilepsia 30 (Suppl.), 51 (1989).
22. Levy R.H., Mattson R.H., Meldrum B.S., Perucca E.: Antiepileptic Drugs (Fifth Ed.), section 1, chapter 3, Lippincott Williams & Wilkins, Philadelphia, PA 2002.
23. Brown W.C.: Epilepsia 2, 127 (1953).
24. Brown W.C., Schiffman D.O., Swinyard E.A., Goodman L.S.: J. Pharmacol. Exp. Ther. 107, 273 (1953).
25. Toman J.E.P.: Neurology 1, 444 (1951).
26. Toman J.E.P., Everett G.M., Richards R.K.: Tex. Rep. Biol. Med. 10, 96 (1952).
27. Barton M.E., Klein B.D., Wolf H.H., White H.S.: Epilepsy Res. 47, 217 (2001).
28. Coulter D.A., Huguenard J.R., Prince D.A.: Ann. Neurol. 25, 582 (1989).
29. Duncan J.S., Sander J.W., Sisodiya S.M., Walker M.C.: Lancet 367, 1087 (2006).